TGTX has mostly buy ratings - i'd look for new coverage from a few institutions as a positive - such as Merrill initiating coverage - and higher price targets. Roth has a high target right now - but they often do - i'd like to see the others stuck at a PT of 22 move up to 30. We'll see.
yes - i think they wanted to raise cash to fund a number of new trials, including some phase III trials that have not been announced yet or initiated but will by the end of 2015
i think it looks great. The response rates (ORR) and other measures (CR and PR) look very compelling in high risk patients - and the adverse events (AEs) are remarkably low. It's clear to me that 1202 will ultimately get approved and be used flexibly by oncologists for CLL and other lymphomas - it'll become a mainstay aspect of combo therapies. 1101 too - but i'm really positive on 1202. Maybe the immuno oncology stocks are getting all the attention - i have to believe that big pharma is seriously evaluating TGTX
Frankly, not sure why it's depressed today. I thought it would be up a few bucks because the data released thus far is great and continues to get better with new triplet therapies being proposed. i've held TGTX since it was below 5 - but i think i'm frustrated with the recent inability to stay closer to 20. I hope the CEO lays off the ATM for a while - that should help a great deal.
yes - it's a new study. I know it includes MRK's drug but i'm not sure how or whether MRK is otherwise involved in the study - perhaps supplying the drug? Not sure.
Yes- i think we are seeing very compelling efficacy with very low and manageable AEs. I'm looking forward to the triple therapy data tomorrow.
And for INFI's IPI-145, they just reported an ORR of 88% in treatment naive CLL (which obviously is not same as rel/ref CLL) but with pretty bad AEs = diarrhea (22%), hepatic ALT/AST elevation (17%) and neutropenia (28%). These AEs will significantly limit combination possibilities in my view, but INFI will try anyway. INFI also has a poster for patients in CLL who are relapsed or refractory following BTK inhibitor (ibrutinib) treatment - that should be interesting - but haven't seen data on this yet.
yeah - i agree. For ibrutinib, i've seen an ORR of 71% in relapsed CLL but with grade 3 or higher patients getting pneumonia (12%) and neutropenia (15%). In contrast, higher doses of 1202 achieved ORR 63% in similar setting with grade 3 or higher AEs limited to about same level of neutropenia. For 1101 + 1202, ORR in rel/ref CLL 83% with grade 3 or higher AEs limited pretty much to neutropenia (about 24%) which is manageable with dose delays. Basically, in layman terms, this means that both 1202 mono and 1202 + 1101 are highly effective with minimal and manageable AEs. I'm not sure why the stock is not at 25 already.
For mono therapy, in higher dose cohort (800 mg or higher original formulation or any of the micronized formulations), ORR = 63% in relapsed/refractory CLL
yes - i think the ATM has influenced the share price. But i'm still holding as i have faith in both 1101 and 1202, especially 1202.
better than expected data on three fronts - 1202 mono, 1202 + 1101 combo (as good as ibrutinib or ibrutinib plus 1101 at higher doses 1202), and 1202 + 1101 + ibrutinib (efficacy in ibrutinib and/or rituxan refractory patients). that's basically it - if you see this, all is good
Every year there seems to be a post-ASCO pull back so that might happen again this year but hard to say how TGTX will be affected. We know that the data is positive from the abstracts we have seen - but note that it will be updated at ASCO so that could continue to push the stock up and tend to act as a brake against a pull back
You can just look up the abstracts - go to google, type in asco, pull up asco abstract page, type in tgr-1202 - and there you will have all three at your fingertips.
I agree on that point too - TGR1202 is the key asset and TG1101 is effective but, as you say, is more of a free call option.